MedTrace Logo

Clinical Applications of FAPI PET in Solid Tumors

NCT07776899 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-08-20

No results posted yet for this study

Summary

The study systematically evaluates the diagnostic performance of FAPI-RuiJ and FAPI-04 PET/CT or PET/MR in various solid tumor types, and is expected to provide a novel molecular imaging tool for early lesion detection, accurate staging, and recurrence surveillance in patients with solid tumors.

Conditions

Interventions

DIAGNOSTIC_TEST

FAPI-RuiJ

A novel FAP-targeted radiotracer for PET/CT or PET/MR imaging; administered intravenously.

DIAGNOSTIC_TEST

FAPI-04

A FAP-targeted radiotracer for PET/CT or PET/MR imaging; administered intravenously.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Biao Li · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-02
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07776899 on ClinicalTrials.gov